PLK1 and cancer: To broadly assess whether FA pathway mutations sensitize to PLK1 inhibitors, we utilized cancer cell line drug sensitivity data publicly available from the Cancer Cell Line Encyclopedia (RRID: SCR_013836; ref. 53).